<DOC>
	<DOC>NCT01656525</DOC>
	<brief_summary>Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.</brief_summary>
	<brief_title>A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&amp;Apos;s Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Have a diagnosis of probable AD dementia, based on NINCDS/ADRDA criteria Meet DSMIV criteria for Dementia of the Alzheimer type MMSE score : 16 to 26 etc. Meet the exclusion criteria of MRI at screening. A history of significant neurodegenerative diseases or dementia other than Alzheimer's disease. etc.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>